INFU vs. AXGN, BFLY, SMLR, DCTH, TMCI, OM, NPCE, CLPT, NNOX, and SKIN
Should you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include AxoGen (AXGN), Butterfly Network (BFLY), Semler Scientific (SMLR), Delcath Systems (DCTH), Treace Medical Concepts (TMCI), Outset Medical (OM), NeuroPace (NPCE), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), and Beauty Health (SKIN). These companies are all part of the "medical equipment" industry.
InfuSystem vs. Its Competitors
AxoGen (NASDAQ:AXGN) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.
InfuSystem has a net margin of 1.12% compared to AxoGen's net margin of -3.68%. InfuSystem's return on equity of 2.78% beat AxoGen's return on equity.
AxoGen presently has a consensus price target of $24.50, indicating a potential upside of 106.06%. InfuSystem has a consensus price target of $13.00, indicating a potential upside of 124.14%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts plainly believe InfuSystem is more favorable than AxoGen.
In the previous week, AxoGen had 1 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for InfuSystem. AxoGen's average media sentiment score of 1.19 beat InfuSystem's score of 0.59 indicating that AxoGen is being referred to more favorably in the media.
InfuSystem has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 2.8% of AxoGen shares are owned by company insiders. Comparatively, 11.4% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
AxoGen has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.
Summary
InfuSystem beats AxoGen on 11 of the 17 factors compared between the two stocks.
Get InfuSystem News Delivered to You Automatically
Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InfuSystem Competitors List
Related Companies and Tools
This page (NYSE:INFU) was last updated on 7/12/2025 by MarketBeat.com Staff
